Biomarkers in Exhaled Breath Condensates of Septic Patients to Predict Development of Multi-organ Dysfunction Syndrome
Recruitment status was Recruiting
In this proposal, the investigators wish to investigate, identify and validate potential biomarkers in collected exhaled breath condensates (EBC) from patients with sepsis.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Biomarkers in Exhaled Breath Condensates of Septic Patients to Predict Development of Multi-organ Dysfunction Syndrome|
- Development and severity of sepsis [ Time Frame: 28 days ] [ Designated as safety issue: No ]To record APACHE II, SOFA, and MODS, etc.
- Mortality [ Time Frame: 28 days ] [ Designated as safety issue: No ]
- Response to treatment and progression of organ failure [ Time Frame: 28 days ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Exhaled breath condensate
|Study Start Date:||August 2011|
Patients with sepsis
Patients who are admitted to ICU with the diagnosis of sepsis
Other: Determined by intended physician
We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
In this proposed project, we will focus on the identification of potential biomarkers in EBC with ability to predict development of multi-organ failure. Currently, no tools could be used to evaluate the effect of mitochondrial dysfunction in sepsis. All the human studies discussing mitochondrial dysfunction in sepsis use tissue biopsies as study materials. Repeated tissue biopsy is invasive and not applicable. EBC could be collected non-invasively and conveniently. A study has demonstrated the use of metabolomic technologies in mitochondrial diseases. We believe that the metabolomic biomarkers of EBC could be used to demonstrate mitochondrial dysfunction in lungs and respiratory tracts of septic patients. Such metabolomic biomarkers may also reflect similar on-going mitochondrial dysfunction in other organ systems, and could potentially become a novel diagnostic tool and a therapeutic target in future sepsis therapy.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01503684
|Contact: Jih-Shuin Jerng, MD,PhDfirstname.lastname@example.org|
|National Taiwan University Hospital||Recruiting|
|Taipei, Taiwan, 100|
|Contact: Jih-Shuin Jerng, MD, PhD 886-2-23562905 email@example.com|
|Principal Investigator: Jih-Shuin Jerng, MD, PhD|
|Principal Investigator:||Jih-Shuin Jerng, MD, PhD||National Taiwan University Hospital|